logo
Gwyneth Paltrow and Serena Williams are both fans of neuromodulation – but what is it and how does it work?

Gwyneth Paltrow and Serena Williams are both fans of neuromodulation – but what is it and how does it work?

Yahoo4 days ago

For most, the idea that you might don a headset to zap your depression away or use electromagnetic pulses to sharpen your cognition seems better placed in a science fiction novel from the 1930s than modern neuroscience, but these kinds of treatments are more common than you might think.
In fact, you can now buy 'vagus reset' gadgets to practice what's broadly referred to as 'neurostimulation' or 'neuromodulation' at home – Instagram and Tiktok are awash with ads for them. And for more intense forms of this kind of technology, a quick online search will deliver a range of private clinics offering 'repetitive transcranial magnetic stimulation' to treat depression and anxiety.
Tennis legend Serena Williams and Goop founder Gwyneth Paltrow are among those who've checked into a private facility to undergo a treatment like this. The athlete recently shared a sponsored Instagram post about her 'ExoMind' journey, describing the treatment as a form of self care. Wellness magnate Paltrow posted a similar story on her Instagram, showing a glowing device attached to her head while she lay on a table.
The company responsible for ExoMind describes the treatment as 'a workout for your mind. An FDA-cleared for the treatment of depression'. The company also offers treatments that use electric pulses to tone and strengthen muscles all over the body – from the stomach to the pelvic floor.
But naturally, both Williams' and Paltrow's Instagram posts have prompted some confusion about possible uses for neuromodulation, delivery methods and who should be using technology like this. Do we need to be nudging our brains with electrical stimuli for improved 'mental fitness'? Or should we just stick with mindfulness apps and fish oil supplements for better brain health?
Furthermore, is stimulating the brain actually a serious cure for depression? Do you need to visit a clinic or will an at-home headset deliver the same results? And most importantly, is this all safe?
Neurostimulation is the act of stimulating the brain, spinal cord or peripheral nerves to modulate neuronal activity. There are a variety of ways to do this and types of neurostimulation vary. For example, a headset that you can buy online without a prescription that promises to 'reset your vagus nerve' is not the same as an in-clinic transcranial stimulation session delivered by a qualified practitioner.
The Flow headset, for example, sends the equivalent current of an AA battery directly to the dorsolateral prefrontal cortex, 'targeting depression at its source to help relieve symptoms'. Rival company Neurosym claims that its device emits precise electrical pulses for 'safe stimulation of vagus nerve fibres'. The company isn't clear on how this approach differs from Flow's, but it does claim that the device activates the parasympathetic nervous system to 'effectively manage chronic pain, fibromyalgia, gut problems, long-covid symptoms, inflammation, POTS symptoms, fatigue, sleep issues, HRV issues, ADHD symptoms, stress, anxious and depressive thoughts and more'. Quite the list of claims.
Pulsetto, another headset that you can use at home, also describes itself as a 'vagus stimulator'. Pulsetto technology uses the lowest form of bluetooth energy – ultra low radiofrequency energy (ULRE) – which according to the brand, 'passes safely into the body to biohack your parasympathetic nervous system'.
'These headsets have great branding but in reality you don't know the exact effects that treatment is going to have on you,' says Adam O'Hagan, specialist rTMS practitioner and coordinator at Priory Wellbeing Centre Harley Street.
'The do-it-yourself kits have shown to be effective but not as much as in controlled settings. Some headsets use rTMS in low levels but they're very different to what we do. They can be more cost effective but use different technologies and these can be significantly less effective.'
Read more: 14 best mindfulness apps to help you keep calm during a crisis
The kind of treatment offered at Priory differs vastly from headsets like Flow and Neurosym – technologies that you can easily buy online albeit for a high price point. Technically, all treatments fall under the umbrella of neurostimulation, but there are significant differences when it comes to the technology and frequencies used, and the applications and results.
The idea with both in-clinic treatments and do-it-yourself headsets is to nudge the areas of the brain that are responsible for emotional regulation, cognitive function and self-control. These areas can often become under-active and this lack of activity is associated with low mood, anxiety, depression and behavioural disorders. Neurostimulation devices generate magnetic pulses to induce electrical currents in the brain, stimulating under-active brain regions.
'An in-clinic session can last about 30 minutes and is typically recommended for treatment-resistant depression, obsessive compulsive disorder, significant eating disorders and anxiety symptoms. The intensity of the machine used is much higher and the treatment is administered by a trained professional,' explains O'Hagan.
'During an rTMS session, electromagnetic coils are placed on your scalp in order to deliver magnetic pulses to your brain. The treatment specifically targets areas of the brain that are involved in mood control, which means it can help to alleviate the symptoms of your mental health conditions and improve wellbeing.'
'The side effects are extremely minimal compared to other treatments such as medication, so it's a much safer and less invasive solution. Some patients can see results after five sessions or around the halfway mark in the treatment plan,' he adds.
It's worth noting that rTMS is very different to electroconvulsive therapy, or ECT, which sends a seizure-inducing current through the brain. Doctors have used ECT for almost a century, and though it's still used in some cases, it remains a controversial and rudimentary treatment.
Read more: I tried hypnotherapy to cure my anxiety and noticed results after just one session
At the other end of the neurostimulation spectrum are home devices – headsets that deliver a mild electrical current to the brain and that can be worn daily on the head or neck. These devices offer 'improved mental fitness' – a catch-all term that seems to comprise several indicators of good health such as boosted mood, lower anxiety levels, improved memory and cognition, and better focus.
The biohacking and longevity crowd are especially keen on the idea of fitness for your mind – Bryan Johnson wears a Pulsetto headset in his Netflix documentary Don't Die. However, Dr Faye Begeti, practising neurology doctor at Oxford University Hospitals and author of The Phone Fix, explains that the term mental fitness is actually quite vague if we're discussing the true benefits of these devices.
'The term 'mental fitness' allows companies to market these devices without clear scientific backing,' she says. 'While some biohackers report subjective benefits, scientific evidence supporting any substantial long term improvement from these devices is weak.
'Established good brain habits such as adequate sleep, regular exercise, learning new skills to build cognitive reserve, and stress management have stronger evidence for improving brain function over time. Expecting dramatic improvements in memory, focus, or productivity from neurostimulation devices is likely unrealistic.'
But as mental health issues such as anxiety and depression continue to affect large swathes of the UK population, people are looking for alternative sources of support – particularly within biohacking and functional medicine. So despite scant evidence that at-home devices can help – and their hefty price tags – neurostimulation headsets have become incredibly popular.
This might have something to do with the fact that social media is currently flooded with instructional videos on 'how to reset your vagus nerve'. These techniques range from simple massage and acupressure to recommendations for headsets like the Neurosym or Pulsetto.
'The vagus nerve 'reset' trend is a mix of science and misinformation,' explains Dr Begeti. The vagus nerve plays a key role in the parasympathetic nervous system, which helps regulate stress, digestion and heart rate. Activities like spending time in nature, meditation, and breathing exercises can stimulate vagal tone, which may have calming effects – but calling it a 'reset' or a 'detox' is misleading. The nervous system is not something that needs 'resetting' in the way social media often suggests.'
'The issue is that social media often oversimplifies complex neuroscience, making it seem like a single technique is a quick hack for mental health. Instead, it's important to have multiple tools in your toolkit for managing difficult emotions while also seeking professional advice when needed,' she adds.
Read more: An expert says you should be doing these four breathing exercises every day
As Dr Begeti says, there's no one trick to eliminate mental health issues. A healthy diet of gut-friendly foods, regular exercise, quality sleep and other techniques like breathwork, yoga and time in nature can all have a positive impact on the brain and nervous system when combined. In isolation, a neurostimulation device won't make much difference if you're not taking good care of yourself.
However, the most recent studies on the effects of clinical rTMS are promising. 'We are witnessing a growing mental health crisis,' explains O'Hagan. 'Depression is treatable, but for some people, medication and psychotherapy do not provide relief. In such cases, rTMS is a really incredible new tool.'
The important thing is not to downplay the intensity of a treatment like this. Though it's akin to tickling your brain, one should be aware of the risks. Various studies have shown that neurostimulation can help improve mood, but a small number of patients have experienced long term effects like tinnitus, cognitive impairment, behavioural changes and short term memory loss.
These outcomes are far less likely with an at-home treatment as the power generated by a wearable isn't comparable to an in-clinic rTMS treatment. However, there are still risks associated with using one. You are, after all, giving your brain a buzz, regardless of the dose.
'The biggest concern is that many brands do not disclose the exact stimulation parameters, making it difficult to know what effect the device is actually having. Additionally, improper use – such as applying stimulation to the wrong area of the brain – could lead to unintended effects,' says Dr Begeti.
She advises researching the frequency and intensity used in detail and checking if the device has been tested in peer-reviewed studies, rather than relying on general research. She also recommends checking for FDA approval or CE certification for specific medical conditions, as opposed to general wellness claims, and reading the instructions thoroughly.
'For low mood, anxiety and issues with feeling dysregulated, a headset could help,' says O'Hagan. However, the best course of action is to use a wearable in conjunction with other healthy habits. These devices are definitely not a magic bullet and O'Hagan recommends using them alongside other interventions like talking therapy and daily self care routines.
'Typically I wouldn't recommend them for people with clinical depression,' he says. But this is where a treatment like clinical rTMS might make a difference, particularly if you've tried other treatments and found them inconsistent or unhelpful.
Our collective understanding of mental health issues is progressing as we find new ways to support and foster good mental health and to treat chronic life-altering problems. Hacking the brain with electromagnetic pulses is clearly just the beginning. But if you're keen to become a brain biohacker yourself, be sure to cast a critical eye over claims you see online, consult with experts and always do your research before trying a new treatment.
Read more: How to spot the symptoms of burnout and treat them, according to wellbeing experts

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines
Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

Yahoo

time2 hours ago

  • Yahoo

Hikma Pharmaceuticals USA announces $1 Billion of new US investment to further expand its domestic manufacturing and development of essential generic medicines

Next phase builds on 34+ years of serving the needs of US patients and healthcare providers COLUMBUS, Ohio, June 28, 2025 /PRNewswire/ -- In its ongoing mission to help meet America's growing need for high-quality US-made medicines, Hikma Pharmaceuticals USA today announces it will invest $1 billion by 2030 to further expand its US manufacturing and R&D capabilities. This new phase of investment -- America Leans on Hikma: Quality Medicines Manufactured in the USA – will further expand Hikma's well-established domestic capabilities to develop, produce and deliver a broad range of medicines needed by the US healthcare system to treat patients nationwide. Hikma has operated in the US since 1991 and has spent more than $4 billion over the past 15 years to build, enhance and expand its US-based R&D and manufacturing capabilities and now has annual domestic capacity to produce more than 12 billion finished doses of essential medicines. Over this period, Hikma has provided patients with access to a wide range of generic medicines at a lower cost than branded products. The company has an excellent record of US FDA quality inspections and has a successful record of working with FDA to solve critical drug shortages. Elected officials including US Rep. Mike Carey (OH-15) and US Rep. Buddy Carter (GA-01) joined Hikma at a special groundbreaking event held at the Company's state-of-the-art pharmaceutical manufacturing and R&D facility in Columbus, Ohio. America Leans on Hikma represents the Company's latest efforts to increase the volume of essential medicines it develops and produces across its R&D and manufacturing sites in Columbus and Cleveland, Ohio and in Cherry Hill and Dayton, New Jersey. This next phase of expansion will help to strengthen Hikma's portfolio of more than 800 medicines and increase the Company's US-based capacity to produce large volumes of high-quality and affordable medicines for American hospitals, providers and patients. "We are proud to continue our ongoing investments in US manufacturing and R&D to better serve the needs of American patients," said Dr. Hafrun Fridriksdottir, President, Hikma Rx. "Hikma and our 2,300 dedicated US people are committed to supporting healthier communities nationwide by providing Americans with a steady and reliable supply of domestically produced quality medicines." Dr. Bill Larkins, President, Hikma Injectables added, "Over the past 15 years Hikma has grown to become a top three US supplier of sterile injectable medicines by volume with more than 180 injectable products in our portfolio and a growing pipeline. This new phase of US investment will enhance and expand our sterile injectables production capabilities and enable us to continue providing our broad portfolio of essential medicines to US patients." "As a pharmacist and Chairman of the American-Made Medicines Caucus, I understand the crucial role Hikma and other generic manufacturers play in delivering affordable and accessible medicines to Americans. It's important that we onshore the production of these critical drugs. I will continue working with Hikma to strengthen our national security and public health by making life-saving generic medications here, in America, and applaud them for their announcement today," said Rep. Buddy Carter. "Hikma continues to invest in American workers and I am thrilled that they have chosen to continue that commitment here in Columbus. This development will support a critical industry and create more jobs for working families in central Ohio. Additional manufacturing capacity will increase Americans' access to high-quality, affordable medicines. I am proud to join Hikma here today to support their mission and the Ohioans they employ. I look forward to returning to see the new facility once it is complete," Rep. Carey said. Hikma remains steadfast in its mission to provide affordable and accessible health care solutions. With this continued investment, Hikma reaffirms its commitment to ensuring a reliable supply of essential medications for all Americans. Contacts : Hikma Pharmaceuticals PLC Investors Susan Ringdal EVP, Strategic Planning and Global Affairs +44 (0)20 7399 2760/ +44 7776 477050 Media Steven Weiss US Communications +1 732 788 8279 About Hikma(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated BBB/stable S&P and BBB/stable Fitch) Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: View original content to download multimedia: SOURCE Hikma Pharmaceuticals USA Inc.

Mountain Hiker, 26, Develops 'Weird Cough'—Then Comes Shock Diagnosis
Mountain Hiker, 26, Develops 'Weird Cough'—Then Comes Shock Diagnosis

Newsweek

time3 hours ago

  • Newsweek

Mountain Hiker, 26, Develops 'Weird Cough'—Then Comes Shock Diagnosis

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A keen mountain climber thought he was just feeling under the weather when he developed a strange cough last year. But when he started to cough up blood, that's what changed his life forever. In the summer of 2024, Bohdan Suprun became increasingly fatigued, but as he was just 26 years old and felt fine otherwise, he didn't think much of it. He'd started hiking in the mountains in Switzerland, noting that his "lungs were performing well" throughout those challenges. But by late August, Suprun, now 27, told Newsweek that he developed a "weird cough that wouldn't go away" and a low-grade fever. The longer that continued, Suprun started to notice chest pains and severe night sweats that caused him to wake up completely drenched. "I thought it was weird since I didn't have any other typical flu-like symptoms. There was no running nose and not even a sore throat," Suprun said. Bohdan Suprun before his diagnosis, pictured snowboarding and hiking. Bohdan Suprun before his diagnosis, pictured snowboarding and hiking. @praesidens / TikTok Soon enough, he started to cough up blood, which felt "serious and disturbing." Something was clearly wrong, and it wasn't just a simple cough. He scheduled a doctor's appointment and went for a blood test to find out what could be causing his mystery illness. The results showed shockingly high levels of C-reactive protein (CRP), a protein made by the liver. His CRP level wasn't just slightly higher than normal, but "multiple times above the threshold." High CRP can be a sign of inflammation, possibly due to a serious infection or chronic disease. As a result, doctors believed that Suprun could have pneumonia, so they prescribed him antibiotics to fight it off. "Initially, the doctor prescribed antibiotics for one week, but the symptoms were getting worse, so I scheduled another appointment," Suprun said. "I thought it was strange because I regularly went up the mountain nearby. So randomly getting pneumonia was just weird." Deep down, Suprun knew it wasn't just an infection, and he returned to the doctors to push for answers. He was still coughing up blood and he lost around 22 pounds in just a matter of weeks, so he had an X-ray to get a better look at his chest. In that moment, Suprun recalls how his doctor's face changed instantly, before he uttered the words: "We have very bad news for you." Bohdan Suprun after being diagnosed with cancer in 2024. Bohdan Suprun after being diagnosed with cancer in 2024. @praesidens / TikTok The X-ray showed a mass on his lung, so Suprun was given two possible scenarios: lung cancer, or tuberculosis. "The probability of those outcomes was very low because I don't smoke and I'm still young. So, they scheduled a CT with contrast for that same day, and the contrast revealed the lung tumor and multiple affected lymph nodes in the lungs," Suprun continued. "The tumor board suggested it was something infectious rather than cancerous, so they kept treating me with antibiotics for another month or so. I told them a few times that it didn't help, and the symptoms didn't improve." He just felt worse and worse as the days passed by. Once it was clear that the antibiotics weren't working, he was taken for another CT scan. To their horror, doctors saw that the tumor had grown aggressively. By then, it was 7x6 centimeters in size, and a biopsy was the only way to find out the real diagnosis. In the end, it wasn't pneumonia or tuberculosis—it was in fact Hodgkin's lymphoma. The stage 4 cancer had spread outside Suprun's lymphatic system and formed a tumor in his lung. He said: "I felt both shocked and relieved. Shocked because of the fact of the diagnosis, and relieved because I finally knew what it was after two months." Bohdan Suprun after undergoing chemotherapy to treat his cancer in 2024. Bohdan Suprun after undergoing chemotherapy to treat his cancer in 2024. @praesidens / TikTok Treatment needed to begin straight away, and Suprun has since undergone six grueling cycles of chemotherapy over a span of three months. Thankfully, the treatment appears to have worked, and recent scans have shown no trace of cancer. Although Suprun is still experiencing some lasting symptoms. He told Newsweek: "I still have some pain in the area where the tumor was located, but it's not too severe. My energy levels are not that high yet, and the worst is the polyneuropathy. The tips of my fingers are numb, and my toes are also numb." As he faces his road to recovery, Suprun has been sharing his experience on TikTok (@praesidens) to educate and inspire others. There were so many times that he felt uncertain about what was going on with his body, and times when he felt alone on this journey. Now he hopes to prevent others from feeling that way too. He's been amazed by the online response, with one post detailing "the cough that changed everything" going viral with over 388,400 views and 23,600 likes at the time of writing. Being diagnosed with cancer at 26 was an intensely difficult challenge, but he's so relieved to have pushed through and to raise awareness. Looking back now, it amazes him to think of what he went through when the symptoms started. He often reflects and wishes it was just a case of the flu after all. Suprun said: "I am happy to survive this, but there are so many other people affected by cancer. So many of life's problems are not problems anymore when you are getting chemo in a hospital bed and fighting for your life. I posted on TikTok after I received the news about being in remission, and the response was very positive." Is there a health issue that's worrying you? Let us know via health@ We can ask experts for advice, and your story could be featured on Newsweek.

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential
10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

Yahoo

time3 hours ago

  • Yahoo

10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential

The healthcare sector offers an abundance of high-growth investment opportunities. Companies leveraging artificial intelligence and genomic medicine are delivering innovative therapies with significant potential. Small-cap and under-the-radar stocks with strong growth possibilities merit closer investor attention. 10 stocks we like better than TransMedics Group › There's a strong case that healthcare is the most important sector in the stock market. These companies deliver innovative therapies and medical technologies that are often life-saving. Investors stand to benefit as healthcare leaders and emerging players address the needs of an aging global population and the rising prevalence of chronic diseases. Here are 10 under-the-radar healthcare stocks that could be great buys for your portfolio. Certara (NASDAQ: CERT) is poised to capitalize on the transformation in medicine driven by artificial intelligence (AI), providing bio-simulation software and services that accelerate drug development. The company plays a crucial role in the pharmaceutical industry. Over 90% of all novel drugs approved by the Food and Drug Administration (FDA) since 2014 have leveraged its technology. Its AI-driven solutions enhance research and development (R&D), enabling faster and more precise drug development. Certara deserves a closer look by investors seeking to tap into the AI-driven healthcare transformation. Beam Therapeutics (NASDAQ: BEAM) is a clinical-stage biotech pioneering precision-based gene editing therapies for genetic diseases, including sickle cell disease. Its innovative technology enables precise single-nucleotide DNA changes, potentially offering a safer alternative to traditional CRISPR genetic engineering. Beam has reported early success in gene correction, with its lead candidate, BEAM-101, in phase 1/2 trials for sickle cell disease. While the company still has a lot to prove, its differentiated approach and clinical progress position it for remarkable growth in the long term. Inspire Medical Systems (NYSE: INSP) develops implantable neurostimulation devices for obstructive sleep apnea, offering its FDA-approved Inspire therapy as a noninvasive alternative to CPAP machines. In its first quarter (the period ended March 31), revenue surged 23% year over year to $201 million, driven by growing U.S. adoption and new international approvals. With increasing demand for sleep apnea treatment, Inspire has a significant opportunity to capture market share. Insulet (NASDAQ: PODD) specializes in tubeless insulin pump technology. Its Omnipod system simplifies diabetes management for Type 1 and insulin-dependent Type 2 patients globally, offering convenience and improved outcomes. With a 2025 revenue growth target of 19% to 22%, the company is poised for continued expansion, particularly in underpenetrated international markets. Insulet's strong growth trajectory positions it to reward shareholders further. Krystal Biotech (NASDAQ: KRYS) focuses on rare skin diseases. Its FDA-approved gene therapy, Vyjuvek, for dystrophic epidermolysis bullosa (fragile skin that blisters easily) is expected to approach $400 million in revenue this year, solidifying its position as a best-in-class treatment. Vyjuvek's success validates Krystal's R&D, bolstering confidence in its pipeline and unlocking added market potential. LifeMD (NASDAQ: LFMD) operates a telehealth platform providing specialized virtual care in weight loss, men's health, and dermatology. A partnership with Novo Nordisk to offer Wegovy, a leading GLP-1 treatment, has driven impressive growth, with first-quarter revenue surging 49% year over year for the period ended March 31. LifeMD could expand its growing user base into a comprehensive health management ecosystem to fuel growth and solidify its telehealth leadership. Option Care Health (NASDAQ: OPCH) is the leading U.S. provider of home and alternative-site infusion services, delivering crucial therapies for chronic and acute conditions like cancer, immune deficiencies, and infections. As the healthcare industry shifts toward more personalized and cost-effective care, Option Care Health is in position to capitalize on the strong demand, with its extensive network and high-quality services. Tempus AI (NASDAQ: TEM) harnesses artificial intelligence to advance precision medicine, using its collection of clinical and molecular data from more than 40 million patients to power diagnostics in oncology, cardiology, and beyond. The company projects its revenue to climb by more than 80% this year, to about $1.3 billion. Tempus AI's scalable platform and extensive data ecosystem present substantial opportunities for expansion and impact in personalized healthcare. TransMedics Group (NASDAQ: TMDX) has revolutionized organ transplantation with its Organ Care System (OCS), the only FDA-approved device for heart, lung, and liver transplants that extends organ preservation time. The company's projected revenue growth of 30% this year underscores the strong momentum in a global expansion opportunity. Veeva Systems (NYSE: VEEV) offers cloud-based software that streamlines clinical, regulatory, and commercial processes for life sciences companies. Serving over 1,000 customers, including major pharmaceutical companies and emerging biotechs, Veeva's platform is well positioned to capitalize on the industry's increasing reliance on digital solutions for innovation and compliance. Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and TransMedics Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Dan Victor has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Beam Therapeutics, Inspire Medical Systems, TransMedics Group, and Veeva Systems. The Motley Fool recommends Insulet, Krystal Biotech, and Novo Nordisk. The Motley Fool has a disclosure policy. 10 Under-the-Radar Healthcare Stocks With Incredible Growth Potential was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store